Cencora (NYSE:COR) Issues FY 2026 Earnings Guidance

Posted by Francis Steltz on Jun 25th, 2026

Cencora (NYSE:COR – Get Free Report) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 17.700-17.900 for the period, compared to the consensus earnings per share estimate of 17.760. The company issued revenue guidance of -.

Wall Street Analysts Forecast Growth

Several research analysts have commented on COR shares. Morgan Stanley set a $342.00 target price on Cencora in a research report on Friday, May 8th. Weiss Ratings downgraded Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 22nd. Bank of America raised their price target on Cencora from $280.00 to $285.00 and gave the company a “neutral” rating in a research note on Wednesday. Barclays decreased their price objective on Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a report on Wednesday, June 10th. Finally, Citigroup lowered their price objective on shares of Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Twelve research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $367.75.

Check Out Our Latest Analysis on Cencora

Cencora Stock Performance

Shares of NYSE:COR opened at $284.94 on Thursday. The firm has a 50 day moving average of $282.09 and a 200 day moving average of $322.80. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. The company has a market capitalization of $55.44 billion, a price-to-earnings ratio of 21.85, a price-to-earnings-growth ratio of 1.52 and a beta of 0.59. Cencora has a 52 week low of $244.82 and a 52 week high of $377.54.

Cencora (NYSE:COR – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The company had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, sell-side analysts predict that Cencora will post 17.79 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. Cencora’s dividend payout ratio is presently 18.40%.

Cencora announced that its Board of Directors has authorized a stock buyback plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to repurchase up to 3.9% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

Insider Transactions at Cencora

In other Cencora news, Director Lauren M. Tyler purchased 550 shares of Cencora stock in a transaction dated Monday, June 22nd. The shares were acquired at an average cost of $270.23 per share, with a total value of $148,626.50. Following the completion of the transaction, the director owned 4,359 shares in the company, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.38% of the company’s stock.

Institutional Investors Weigh In On Cencora

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in COR. Beacon Pointe Advisors LLC boosted its holdings in Cencora by 1.1% in the fourth quarter. Beacon Pointe Advisors LLC now owns 3,492 shares of the company’s stock worth $1,180,000 after acquiring an additional 37 shares in the last quarter. Parkside Financial Bank & Trust increased its holdings in shares of Cencora by 2.2% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,784 shares of the company’s stock valued at $603,000 after acquiring an additional 38 shares in the last quarter. Sumitomo Life Insurance Co. raised its position in shares of Cencora by 0.9% in the 4th quarter. Sumitomo Life Insurance Co. now owns 4,462 shares of the company’s stock valued at $1,507,000 after purchasing an additional 39 shares during the last quarter. Evergreen Capital Management LLC raised its position in shares of Cencora by 3.8% in the 2nd quarter. Evergreen Capital Management LLC now owns 1,233 shares of the company’s stock valued at $370,000 after purchasing an additional 45 shares during the last quarter. Finally, Mission Creek Capital Partners Inc. boosted its stake in Cencora by 5.1% in the 4th quarter. Mission Creek Capital Partners Inc. now owns 1,158 shares of the company’s stock worth $391,000 after purchasing an additional 56 shares in the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

About Cencora

(Get Free Report)

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.